Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT04811404

A PET Study With [11C]PBR-28 and an Experimental Medication, Ethyl Eicosapentaenoic Acid

Status
Withdrawn
Phase
Phase 4
Study type
Interventional
Enrollment
0 (actual)
Sponsor
New York State Psychiatric Institute · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

This pilot study will ask whether omega three fatty acids have an antidepressant effect in bipolar depression by decreasing brain inflammation.

Conditions

Interventions

TypeNameDescription
DRUGEthyl Eicosapentaenoic AcidTreatment will be for six weeks

Timeline

Start date
2021-03-19
Primary completion
2022-07-01
Completion
2022-07-01
First posted
2021-03-23
Last updated
2022-10-14

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT04811404. Inclusion in this directory is not an endorsement.

A PET Study With [11C]PBR-28 and an Experimental Medication, Ethyl Eicosapentaenoic Acid (NCT04811404) · Clinical Trials Directory